skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Patient perspectives on use of long-acting antipsychotics in bipolar disorder: focus on risperidone injection

Review

(1832) Views  (472) Full article downloads

Authors: L Samalin, T Charpeaud, O Lorabi, et al

Published Date August 2010 Volume 2010:4 Pages 325 - 334
DOI: http://dx.doi.org/10.2147/PPA.S7647

L Samalin, T Charpeaud, O Lorabi, PM Llorca

Centre Hospitalier Universitaire, Clermont-Ferrand, France

Abstract: In the last few years, oral second-generation antipsychotics have demonstrated mood-stabilizing properties and are now widely used in the treatment of bipolar disorder. Unfortunately, treatment of this chronic and complex illness is hampered with poor adherence on the part of patients. Long-acting injectable formulations of second-generation antipsychotics could combine the effect of oral second-generation antipsychotics in patients with bipolar disorder and the benefits of depot formulation with the assurance of steady medication delivery and thereby improve adherence. In this context, the efficacy and tolerance of risperidone long-acting injection (RLAI) for maintenance treatment in patients with bipolar disorder is assessed. The relevant studies found RLAI to be effective in preventive treatment of manic but not depressive recurrences in bipolar patients, with good tolerance. RLAI appeared to be particularly suitable for patients with known poor adherence to treatment or severe bipolar disorder (such as patients who relapse frequently). Lastly, if RLAI, unlike the first-generation antipsychotics, does not induce depressive symptoms, the different studies do not enable us to consider its use in monotherapy in the preventive treatment of patients with depressive polarity. Long-acting second-generation antipsychotics in bipolar patients are therefore associated with long-term benefits, but their use in clinical practice needs to be improved.

Keywords: bipolar disorder, depot antipsychotics, long-acting risperidone injection, ­maintenance treatment, compliance







Readers of this article also read:

Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
Patient perspectives in the management of asthma: improving patient outcomes through critical selection of treatment options
Exploring patients’ perceptions for insulin therapy in type 2 diabetes: a Brazilian and Canadian qualitative study
The utility of an electronic adherence assessment device in type 2 diabetes mellitus: a pilot study of single medication
Antipsychotic adherence, switching, and health care service utilization among Medicaid recipients with schizophrenia
Modeling the economic impact of medication adherence in type 2 diabetes: a theoretical approach
Varenicline for smoking cessation: efficacy, safety, and treatment recommendations
A systematic writing program as a tool in the grief process: part 1
Introducing students to patient safety through an online interprofessional course
Clinical development of liposome based drugs: formulation, characterization, and therapeutic efficacy